Over the course of the last decade, the biopharmaceutical industry has slowly adopted human inducible pluripotent stem cell (hiPSC) technology to enable the development of humanized model systems to test new therapeutic molecules and drug modalities. The adoption of hiPSC-based models by the industry has increased appreciably in the past 3–5 years. This increase has paralleled the explosion in availability of high-quality human genetic data to mine for new drug targets and the emergence of human-specific therapeutic modalities.

中文翻译：

---

人类诱导多能干细胞：实现药物发现的初步前景

在过去十年中，生物制药行业逐渐采用人类诱导多能干细胞 (hiPSC) 技术来开发人性化模型系统，以测试新的治疗分子和药物模式。在过去的 3-5 年中，业界采用基于 hiPSC 的模型的情况显着增加。这种增长与用于挖掘新药物靶点的高质量人类基因数据的可用性激增以及人类特异性治疗方式的出现同时发生。